The FDA granted accelerated approval of linvoseltamab-gcpt for certain patients with multiple myeloma.Specifically, the ...

While it trails Johnson & Johnson’s Tecvayli, Regeneron still hopes Lynozyfic can differentiate in terms of dosing ...

Given the advantages over its rivals, Regeneron is hopeful its bispecific antibody will become the new standard of care for ...

The FDA has granted accelerated approval to linvoseltamab-gcpt (Lynozyfic) for the treatment of adult patients with ...

The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a ...

Disparities in multiple myeloma outcomes and the need for equitable care were the focus of 2 posters presented at the 2025 ...

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...

Single-dose CAR-T therapy potentially curative in multiple myeloma by Justin Jackson, Phys.org edited by Sadie Harley, reviewed by Robert Egan Editors' notes ...

For patients newly diagnosed with multiple myeloma, optimal outcomes start with a clear set of goals. "The primary goals of initial treatment are straightforward: relieve symptoms like anemia ...

Multiple myeloma causes lytic or osteolytic lesions, which are areas of damage caused by cancerous plasma cells blocking normal bone growth. While painful, they can be managed. Multiple myeloma is ...

A B-cell maturation antigen (BCMA)-directed bispecific antibody, linvoseltamab is indicated for adult patients who have ...